

1 Whole genome sequencing identifies multiple loci for critical
2 illness caused by COVID-19

3
4 Athanasios Kousathanas^{‡,1}, Erola Pairo-Castineira^{‡,2,3}, Konrad Rawlik², Alex Stuckey¹, Christopher
5 A Odhams¹, Susan Walker¹, Clark D Russell^{2,4}, Tomas Malinauskas⁵, Jonathan Millar², Katherine
6 S Elliott⁵, Fiona Griffiths², Wilna Oosthuyzen², Kirstie Morrice⁶, Sean Keating⁷, Bo Wang², Daniel
7 Rhodes¹, Lucija Klaric³, Marie Zechner², Nick Parkinson², Andrew D. Bretherick³, Afshan Siddiq¹,
8 Peter Goddard¹, Sally Donovan¹, David Maslove⁸, Alistair Nichol⁹, Malcolm G Semple^{10,11}, Tala
9 Zainy¹, Fiona Maleady-Crowe¹, Linda Todd¹, Shahla Salehi¹, Julian Knight⁵, Greg Elgar¹, Georgia
10 Chan¹, Prabhu Arumugam¹, Tom A Fowler^{12,13}, Augusto Rendon¹, Manu Shankar-Hari¹⁴, Charlotte
11 Summers¹⁵, Paul Elliott¹⁶, Jian Yang¹⁷, Yang Wu, GenOMICC Investigators, 23andMe, Covid-19
12 Human Genetics Initiative, Angie Fawkes⁶, Lee Murphy⁶, Kathy Rowan¹⁸, Chris P Ponting³,
13 Veronique Vitart³, James F Wilson^{3,19}, Richard H Scott^{1,20}, Sara Clohisey^{*,2}, Loukas Moutsianas^{*,1},
14 Andy Law^{*,2}, Mark J Caulfield^{*,12,21}, J. Kenneth Baillie^{*,2,3,4,7}.

15 ‡ - joint first authors

16 * - joint last authors

17 ¹Genomics England, London UK

18 ²Roslin Institute, University of Edinburgh, Easter Bush, Edinburgh, EH25 9RG, UK

19 ³MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh,
20 Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK

21 ⁴Centre for Inflammation Research, The Queen's Medical Research Institute, University of Edinburgh,
22 47 Little France Crescent, Edinburgh, UK

23 ⁵Wellcome Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN,
24 UK

25 ⁶Edinburgh Clinical Research Facility, Western General Hospital, University of Edinburgh, EH4
26 2XU, UK

27 ⁷Intensive Care Unit, Royal Infirmary of Edinburgh, 54 Little France Drive, Edinburgh, EH16 5SA,
28 UK

29 ⁸Department of Critical Care Medicine, Queen's University and Kingston Health Sciences Centre,
30 Kingston, ON, Canada

31 ⁹Clinical Research Centre at St Vincent's University Hospital, University College Dublin, Dublin,
32 Ireland

33 ¹⁰NIHR Health Protection Research Unit for Emerging and Zoonotic Infections, Institute of Infection,
34 Veterinary and Ecological Sciences University of Liverpool, Liverpool, L69 7BE, UK

35 ¹¹Respiratory Medicine, Alder Hey Children's Hospital, Institute in The Park, University of Liverpool,
36 Alder Hey Children's Hospital, Liverpool, UK

37 ¹²Genomics England, Queen Mary University of London

38 ¹³Test and Trace, the Health Security Agency, Department of Health and Social Care, Victoria St,
39 London, UK

40 ¹⁴Department of Intensive Care Medicine, Guy's and St. Thomas NHS Foundation Trust, London,
41 UK

42 ¹⁵Department of Medicine, University of Cambridge, Cambridge, UK

43 ¹⁶Imperial College, London

44 ¹⁷Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang 310024, China

45 ¹⁸Intensive Care National Audit & Research Centre, London, UK

46 ¹⁹Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics,
47 Teviot Place, Edinburgh EH8 9AG, UK

48 ²⁰Great Ormond Street Hospital, London UK

49 ²¹William Harvey Research Institute, Queen Mary University of London, Charterhouse Square,
50 London EC1 6BQ

51 **Abstract**

52 Critical illness in COVID-19 is caused by inflammatory lung injury, mediated by the host immune
53 system. We and others have shown that host genetic variation influences the development of illness
54 requiring critical care¹ or hospitalisation^{2;3;4} following SARS-Co-V2 infection. The GenOMICC
55 (Genetics of Mortality in Critical Care) study is designed to compare genetic variants in critically-ill
56 cases with population controls in order to find underlying disease mechanisms.

57 Here, we use whole genome sequencing and statistical fine mapping in 7,491 critically-ill cases
58 compared with 48,400 population controls to discover and replicate 22 independent variants that
59 significantly predispose to life-threatening COVID-19. We identify 15 new independent associations
60 with critical COVID-19, including variants within genes involved in interferon signalling (*IL10RB*,
61 *PLSCR1*), leucocyte differentiation (*BCL11A*), and blood type antigen secretor status (*FUT2*).
62 Using transcriptome-wide association and colocalisation to infer the effect of gene expression
63 on disease severity, we find evidence implicating expression of multiple genes, including reduced
64 expression of a membrane flippase (*ATP11A*), and increased mucin expression (*MUC1*), in critical
65 disease.

66 We show that comparison between critically-ill cases and population controls is highly efficient for
67 genetic association analysis and enables detection of therapeutically-relevant mechanisms of disease.
68 Therapeutic predictions arising from these findings require testing in clinical trials.

69 Introduction

70 Critical illness in COVID-19 is both an extreme disease phenotype, and a relatively homogeneous
71 clinical definition including patients with hypoxaemic respiratory failure⁵ with acute lung injury,⁶
72 and excluding many patients with non-pulmonary clinical presentations⁷ who are known to have
73 divergent responses to therapy.⁸ In the UK, the critically-ill patient group is younger, less likely
74 to have significant comorbidity, and more severely affected than a general hospitalised cohort,⁵
75 characteristics which may amplify observed genetic effects. In addition, since development of critical
76 illness is in itself a key clinical endpoint for therapeutic trials,⁸ using critical illness as a phenotype
77 in genetic studies enables detection of directly therapeutically-relevant genetic effects.¹

78 Using microarray genotyping in 2,244 cases, we previously reported that critical COVID-19 is
79 associated with genetic variation in the host immune response to viral infection (*OAS1*, *IFNAR2*,
80 *TYK2*) and the inflammasome regulator *DPP9*.¹ In collaboration with international groups, we
81 recently extended these findings to include a variant near *TAC4* (rs77534576).⁴ Several variants
82 have been associated with milder phenotypes, such as the need for hospitalisation or management
83 in the community, including the ABO blood type locus,³ a pleiotropic inversion in chr17q21.31,⁹
84 and associations in 5 additional loci including the T lymphocyte-associated transcription factor,
85 *FOXP4*.⁴ An enrichment of rare loss-of-function variants in candidate interferon signalling genes has
86 been reported,² but this has yet to be replicated at genome-wide significance thresholds.^{10;11}

87 We established a partnership between the GenOMICC Study and Genomics England to perform
88 whole genome sequencing (WGS) to improve resolution and deepen fine-mapping of significant
89 signals to enhance the biological insights into critical COVID-19. Here, we present results from a
90 cohort of 7,491 critically-ill patients from 224 intensive care units, compared with 48,400 population
91 controls, describing discovery and validation of 22 gene loci for susceptibility to life-threatening
92 COVID-19.

93 Results

94 Study design

95 Cases were defined by the presence of COVID-19 critical illness in the view of the treating clinician -
96 specifically, the need for continuous cardio-respiratory monitoring. Patients were recruited from
97 224 intensive care units across the UK in the GenOMICC (Genetics Of Mortality In Critical Care)
98 study. As a control population, unrelated participants recruited to the 100,000 Genomes Project
99 were selected, excluding those with a known positive COVID-19 test, as severity information was
100 not available. The 100,000 Genomes Project cohort (100k cohort) is comprised of UK individuals
101 with a broad range of rare diseases or cancer and their family members. We included an additional
102 prospectively-recruited cohort of volunteers (mild cohort) who self-reported testing positive for
103 SARS-CoV-2 infection, and experienced mild or asymptomatic disease.

104 GWAS analysis

105 Whole genome sequencing and subsequent alignment and variant calling was performed for all
106 subjects as described below (Methods). Following quality control procedures, we used a logistic
107 mixed model regression, implemented in SAIGE,¹² to perform association analyses with unrelated

chr:pos (hg38)	rsid	REF	ALT	RAF	pop	OR	OR _{CI}	Pval	HetPVal	Consequence	Gene	Expression
1:155066988	rs114301457	C	T*	0.0058	EUR	2.40	1.82-3.16	6.8×10^{-10}	1	synonymous	<i>EFNA4</i>	-
1:155175305	rs7528026	G	A*	0.032	META	1.39	1.24-1.55	7.16×10^{-9}	0.96	intron	<i>TRIM46</i>	-
1:155197995	rs41264915	A*	G	0.89	EUR	1.28	1.19-1.37	1.02×10^{-12}	0.29	intron	<i>THBS3</i>	<i>MUC1</i>
2:00480453	rs1123573	A*	G	0.61	META	1.13	1.09-1.18	9.85×10^{-10}	0.29	intron	<i>BCL11A</i>	-
3:45796521	rs2271616	G	T*	0.14	EUR	1.29	1.21-1.37	9.9×10^{-17}	0.0011	5' UTR	<i>SLC6A20</i>	<i>SLC6A20</i> , <i>CCR5</i>
3:45859597	rs73064425	C	T*	0.077	EUR	2.71	2.51-2.94	1.97×10^{-133}	0.010	intron	<i>LZTFL1</i>	<i>LZTFL1</i> , <i>CCR9</i>
3:146517122	rs343320	G	A*	0.081	EUR	1.25	1.16-1.35	4.94×10^{-9}	0.53	missense	<i>PLSCR1</i>	-
5:131995059	rs56162149	C	T*	0.17	EUR	1.20	1.13-1.26	7.65×10^{-11}	0.17	intron	<i>ACSL6</i>	<i>ACSL6</i> , <i>FNIP1</i>
6:32623820	rs9271609	T*	C	0.65	EUR	1.14	1.09-1.19	3.26×10^{-9}	0.24	upstream	<i>HLA-DQA1</i>	<i>HLA-DQA1</i> , <i>HLA-DQA2</i>
6:41515007	rs2496644	A*	C	0.015	META	1.45	1.32-1.60	7.59×10^{-15}	0.49	intron	<i>LINC01276</i>	-
9:21206606	rs28368148	C	G*	0.013	EUR	1.74	1.45-2.09	1.93×10^{-9}	1	missense	<i>IFNA10</i>	-
11:34482745	rs61882275	G*	A	0.62	EUR	1.15	1.10-1.20	1.61×10^{-10}	0.29	intron	<i>ELF5</i>	-
12:132489230	rs56106917	GC	G*	0.49	EUR	1.13	1.09-1.18	2.08×10^{-9}	0.90	upstream	<i>FBRSL1</i>	-
13:112889041	rs9577175	C	T*	0.23	EUR	1.18	1.12-1.24	3.71×10^{-11}	0.10	downstream	<i>ATP11A</i>	<i>ATP11A</i>
15:93046840	rs4424872	T*	A	0.0079	EUR	2.37	1.87-3.01	8.61×10^{-13}	1.82×10^{-7}	intron	<i>RGMA</i>	-
16:89196249	rs117169628	G	A*	0.15	EUR	1.19	1.12-1.26	4.9×10^{-9}	0.80	missense	<i>SLC22A31</i>	<i>SLC22A31</i> , <i>CDH15</i>
17:46152620	rs2532300	T*	C	0.77	EUR	1.16	1.10-1.22	4.19×10^{-9}	0.32	intron	<i>KANSL1</i>	<i>ARHGAP27</i>
17:49863260	rs3848456	C	A*	0.029	EUR	1.50	1.33-1.70	4.19×10^{-11}	0.14	regulatory	.	-
19:4717660	rs12610495	A	G*	0.31	EUR	1.32	1.27-1.38	3.91×10^{-36}	0.069	missense	<i>DPP9</i>	-
19:10305768	rs73510898	G	A*	0.093	EUR	1.28	1.19-1.37	1.57×10^{-11}	0.011	intron	<i>ZGLP1</i>	-
19:10352442	rs34536443	G	C*	0.050	EUR	1.50	1.36-1.65	6.98×10^{-17}	0.63	missense	<i>TYK2</i>	<i>TYK2</i> , <i>PDE4A</i>
19:48697960	rs368565	C	T*	0.44	EUR	1.15	1.1-1.2	3.55×10^{-11}	0.22	intron	<i>FUT2</i>	<i>FUT2</i> , <i>NTN5</i> , <i>RASIP1</i>
21:33230000	rs17860115	C	A*	0.32	EUR	1.24	1.19-1.3	9.69×10^{-22}	0.63	5' UTR	<i>IFNAR2</i>	-
21:33287378	rs8178521	C	T*	0.27	EUR	1.18	1.12-1.23	3.53×10^{-12}	0.67	intron	<i>IL1ORB</i>	-
21:33959662	rs35370143	T	TAC*	0.083	EUR	1.26	1.17-1.36	1.24×10^{-9}	1	intron	<i>LINC00649</i>	-

Table 1: Lead variants from independent regions in the per-population GWAS and trans-ancestry meta-analysis. Variants and the reference and alternate allele are reported with hg38 build coordinates. Asterisk (*) indicates the risk allele. For each variant, we report the risk allele frequency in Europeans (RAF), the odds ratio and 95% confidence interval, and the association P -value. Consequence indicates the worst consequence predicted by VEP99, and Gene indicates the VEP99-predicted gene, but not necessarily the causal mediator. Expression indicates genes where is evidence of gene expression affecting COVID-19 severity, found by TWAS and colocalisation analysis.

108 individuals (critically-ill cases $n = 7,491$, controls (100k) $n = 46,770$, controls (mild COVID-
109 19) $n = 1,630$) (Methods, Supplementary Table 2). 1,339 of these cases were included in the
110 primary analysis for our previous report.¹ Genome wide association studies (GWAS) were performed
111 separately for genetically predicted ancestry groups (European - EUR, South Asian - SAS, African
112 - AFR, East Asian - EAS, see Methods). Subsequently, we conducted inverse-variance weighted
113 fixed effects meta-analysis across the four predicted ancestry cohorts using METAL¹³ (Methods).
114 In order to reduce the risk of spurious associations arising from genotyping or pipeline errors, we
115 required supporting evidence from variants in linkage disequilibrium for all genome-wide significant
116 variants: observed z-scores for each variant were compared to imputed z-scores for the same variant,
117 with discrepant values being excluded (see Methods, Supplementary Figure 12).

118 In population-specific analyses, we discovered 22 independent genome-wide significant associations
119 in the EUR ancestry group (Figure 1, Supplementary Figure 11 and Table 1) at a P -value threshold
120 adjusted for multiple testing for 2,264,479 independent linkage disequilibrium-pruned genetic variants:
121 2.2×10^{-08} (Supplementary Table 3). The strong association at 3p21.31 also reached genome-wide
122 significance in the SAS ancestry group (Supplementary Figure 11).

123 In trans-ancestry meta-analysis, we identified an additional three loci with genome-wide significant
124 associations (Figure 1, Table 1). We tested the meta-analysed set of 25 loci for heterogeneity of
125 effect size between predicted ancestries and detected significant (at $P < 1.83 \times 10^{-3}$) evidence for
126 heterogeneity for two variants (Table 1, Supplementary Figure 13).




Figure 1: GWAS results for EUR ancestry group, and trans-ancestry meta-analysis. Manhattan plots are shown on the left and quantile–quantile (QQ) plots of observed versus expected P values are shown on the right, with genomic inflation (λ) displayed for each analysis. Highlighted results in blue in the Manhattan plots indicate variants that are LD-clumped ($r^2=0.1$, $P_2=0.01$, EUR LD) with the lead variants at each locus. Gene name annotation by Variant Effect Predictor (VEP) indicates genes impacted by the predicted consequence type of each lead variant. The red dashed line shows the Bonferroni-corrected P -value= 2.2×10^{-8} .

chr:pos (hg38)	rsid	REF	ALT	OR	OR _{CI}	Pval	OR _{HGI.23m}	OR _{CI.HGI.23m}	Pval _{HGI.23m}	Gene	Citation
1:155066988	rs114301457	C	T	2.40	1.81-3.18	1.51×10 ⁻⁹	1.46	1.21-1.77	0.00011 *	<i>EFNA4</i>	-
1:155175305	rs7528026	G	A	1.39	1.24-1.55	7.16×10 ⁻⁹	1.14	1.07-1.22	0.00012 *	<i>TRIM46</i>	-
1:155197995	rs41264915	A	G	0.80	0.76-0.86	3.79×10 ⁻¹²	0.9	0.87-0.933	1.51×10 ⁻⁹ *	<i>THBS3</i>	-
2:60480453	rs1123573	A	G	0.88	0.85-0.92	9.85×10 ⁻¹⁰	0.95	0.93-0.97	0.000018 *	<i>BCL11A</i>	-
3:45796521	rs2271616	G	T	1.26	1.19-1.34	2.45×10 ⁻¹⁵	1.11	1.07-1.15	4.95×10 ⁻⁹ *	<i>SLC6A20</i>	(⁴)
3:45859597	rs73064425	C	T	2.52	2.35-2.70	2.18×10 ⁻¹⁵²	1.46	1.4-1.51	1.02×10 ⁻⁷⁷ *	<i>LZTFL1</i>	³
3:146517122	rs343320	G	A	1.24	1.15-1.33	1.52×10 ⁻⁸	1.08	1.04-1.13	0.00028 *	<i>PLSCR1</i>	-
5:132441275	rs10066378	T	C	1.20	1.13-1.27	4.48×10 ⁻¹⁰	1.05	1.02-1.08	0.00074 *	<i>IRF1-AS1</i>	-
6:32623820	rs9271609	T	C	0.88	0.84-0.92	1.27×10 ⁻⁸	1	0.98-1.03	0.89	<i>HLA-DQA1</i>	-
6:41515007	rs2496644	A	C	0.69	0.63-0.76	7.59×10 ⁻¹⁵	0.87	0.83-0.92	3.17×10 ⁻⁷ *	<i>LINC01276</i>	-
9:21206606	rs28368148	C	G	1.74	1.45-2.1	4.09×10 ⁻⁹	1.21	1.07-1.37	0.0024	<i>IFNA10</i>	-
11:34482745	rs61882275	G	A	0.87	0.84-0.91	1.62×10 ⁻¹¹	0.93	0.91-0.95	1.9×10 ⁻¹⁰ *	<i>ELF5</i>	-
12:132479205	rs4883585	G	A	1.13	1.09-1.18	1.12×10 ⁻⁹	1.04	1.02-1.06	0.00047 *	<i>FBRSL1</i>	-
13:112889041	rs9577175	C	T	1.18	1.13-1.23	1.61×10 ⁻¹²	1.07	1.04-1.09	1.29×10 ⁻⁶ *	<i>ATP11A</i>	-
15:93046840	rs4424872	T	A	0.64	0.53-0.76	1.99×10 ⁻⁶	-	-	-	<i>RGMA</i>	-
16:89196249	rs117169628	G	A	1.18	1.12-1.25	6.04×10 ⁻⁹	1.1	1.07-1.14	6.57×10 ⁻⁹ *	<i>SLC22A31</i>	-
17:46152620	rs2532300	T	C	0.87	0.82-0.91	1.4×10 ⁻⁸	0.92	0.89-0.94	2.49×10 ⁻⁹ *	<i>KANSL1</i>	⁹
17:49863260	rs3848456	C	A	1.42	1.27-1.58	1.47×10 ⁻¹⁰	1.15	1.09-1.21	1.34×10 ⁻⁷ *	.	⁴
19:4717660	rs12610495	A	G	1.32	1.27-1.38	6.44×10 ⁻³⁹	1.11	1.09-1.14	5.74×10 ⁻¹⁹ *	<i>DPP9</i>	¹
19:10305768	rs73510898	G	A	1.24	1.16-1.33	1.47×10 ⁻⁹	1.08	1.04-1.12	0.00016 *	<i>ZGLP1</i>	-
19:10352442	rs34536443	G	C	1.50	1.37-1.66	4.22×10 ⁻¹⁷	1.22	1.15-1.29	4.06×10 ⁻¹¹ *	<i>TYK2</i>	¹
19:48697960	rs368565	C	T	1.13	1.09-1.18	3.74×10 ⁻¹⁰	1.04	1.02-1.06	0.00087 *	<i>FUT2</i>	-
21:33230000	rs17860115	C	A	1.26	1.21-1.31	6.28×10 ⁻²⁸	1.11	1.08-1.13	1.77×10 ⁻¹⁸ *	<i>IFNAR2</i>	¹
21:33287378	rs8178521	C	T	1.17	1.12-1.22	4.23×10 ⁻¹²	1.06	1.03-1.09	8.02×10 ⁻⁶ *	<i>IL10RB</i>	-
21:33914436	rs12626438	A	G	1.22	1.14-1.31	1.78×10 ⁻⁸	1.1	1.06-1.14	2.33×10 ⁻⁷ *	<i>LINC00649</i>	-

Table 2: Replication in a combined data from external studies - combined meta-analysis of HGI freeze 6 B2 and 23andMe. Odds ratios and *P*-values are shown for variants in LD with the lead variant that were genotyped/imputed in both sources. Chromosome, reference and alternate allele correspond to the build hg38. An asterisk (*) next to the HGI and 23andme meta-analysis *P*-value indicates that the lead signal is replicated with *P*-value<0.002 with a concordant direction of effect. Citation lists the first publication of confirmed genome-wide associations with critical illness or (in brackets) any COVID-19 phenotype.

127 Replication

128 Replication was performed using summary statistics generously shared by collaborators: data from
 129 the COVID-19 Host Genetics Initiative (HGI) data freeze 6 were combined using meta-analysis
 130 with data shared by 23andMe (Methods). Although the HGI programme included an analysis
 131 intended to mirror the GenOMICC study (analysis "A2"), there are currently insufficient cases
 132 from other sources available to attempt replication, so we used the broader hospitalised phenotype
 133 (analysis "B2") for replication. We removed signals in the HGI data derived from GenOMICC cases
 134 using mathematical subtraction (see Methods) to ensure independence. Using LD clumping to find
 135 variants genotyped in both the discovery and replication studies, we required $P < 0.002$ (0.05/25)
 136 and concordant direction of effect (Table 2) for replication.

137 We replicated 22 of the 25 significant associations identified in the population specific and/or
 138 trans-ancestry GWAS. Two of the three loci not replicated correspond to rare alleles that may not be
 139 well represented in the replication datasets which are dominated by SNP genotyping data. Although
 140 not replicated, for rs28368148 (9:21206606:C:G, *IFNA10*) we observed both a consistent direction
 141 of effect and odds ratio. The third locus is within the human leukocyte antigen (HLA) locus (see
 142 below).

143 We inferred credible sets of variants using Bayesian fine-mapping with susieR¹⁴, by analysing the

144 GWAS summaries of 17 3Mbp regions that were flanking groups of lead signals. We obtained 22
145 independent credible sets of variants for EUR and one for SAS that each had posterior inclusion
146 probability > 0.95 .

147 Fine mapping of the association signals revealed putative causal variants for several genes (See
148 Supplementary Information). For example, we detected variants at 3q24 and 9p21.3 predicted to
149 be missense mutations by Variant Effect Predictor (VEP). These impact *PLSCR1* and *IFNA10*
150 respectively, and both are predicted to be deleterious by the Combined Annotation Dependent
151 Depletion (CADD) tool¹⁵ (*PLSCR1* (chr3:146517122:G:A, rs343320,p.His262Tyr, OR:1.24, 95% CIs
152 [1.15-1.33], CADD:22.6; *IFNA10* (chr9:21206606:C:G, rs28368148,p.Trp164Cys, OR:1.74, 95% CIs
153 [1.45-2.09], CADD:23.9). Structural predictions for these loci suggest functional effects (Figure 3
154 and Supplementary Figure 15).

155 Gene burden testing

156 To assess the contribution of rare variants to critical illness, we performed gene-based analysis using
157 SKAT-O as implemented in SAIGE-GENE¹⁶, using a subset of 12,982 individuals from our cohort
158 (7,491 individuals with critical COVID-19 and 5,391 controls) for which the genome sequencing
159 data were processed with the same alignment and variant calling pipeline. We tested the burden of
160 rare (MAF $<0.5\%$) variants considering the predicted variant consequence type. We assessed burden
161 using a strict definition for damaging variants (high-confidence loss-of-function (pLoF) variants as
162 identified by LOFTEE¹⁷) and a lenient definition (pLoF plus missense variants with CADD ≥ 10)¹⁵
163 , but found no significant associations at a gene-wide significance level. All individual rare variants
164 included in the tests had P -values $>10^{-5}$.

165 We then further examined the association with 13 genes involved in the regulation of type I and
166 III interferon immunity that were implicated in critical COVID-19 pneumonia² but, as with other
167 recent studies¹⁰, we did not find any significant gene burden test associations (tests for all genes
168 had P -value >0.05 , Supplementary File AVTsuppinfo.xlsx). We also did not replicate the reported
169 association¹⁰ for the toll-like receptor 7 (*TLR7*) gene.

170 Transcriptome-wide association study

171 In order to infer the effect of genetically-determined variation in gene expression on disease sus-
172 ceptibility, we performed a transcriptome-wide association study (TWAS) using gene expression
173 data (GTEXv8) for two disease-relevant tissues, lung and whole blood. We found 14 genes with
174 significant association between predicted expression and critical COVID-19 in the lung and 6 in
175 whole blood analyses (Supplementary File: TWAS.xlsx). To increase statistical power using eQTLs
176 from multiple tissues, we performed a TWAS meta-analysis using all available tissues in GTEXv8,
177 revealing 51 transcriptome-wide significant genes. Since TWAS uses a composite signal derived
178 from multiple eQTLs, we used colocalisation to find specific eQTLs in whole blood (eqtlGen and
179 GTEXv8) and lung (GTEXv8¹⁸) which share the same signal with GWAS (EUR) associations. We
180 found 16 genes which significantly colocalise in at least one of the studied tissues, shown in Figure 2.

181 We repeated the TWAS analysis using models of intron excision rate from GTEXv8 to obtain splicing
182 TWAS. We found 40 signals in lung, affecting 16 genes and 20 signals in whole blood which affect
183 9 genes. In a meta-analysis of splicing TWAS using all GTEXv8 tissues, we found 91 significant
184 introns in a total of 33 genes. Using GTEXv8 lung and whole blood sqtls to find colocalising

185 signals with splicing TWAS significant results, we found 11 genes with colocalising splicing signals
 186 (Supplementary File: TWAS.xlsx).




Figure 2: Gene-level Manhattan plot showing results from TWAS meta-analysis and highlighting genes that colocalise with GWAS signals or have strong metaTWAS associations. Highlighting color is different for lung and blood tissue data that were used for colocalisation. Arrows show direction of change in gene expression associated with an increased disease risk. Red dashed line shows significance threshold at $P < 2.3 \times 10^{-6}$.

187 HLA region

188 To investigate the contribution of specific HLA alleles to the observed association in the HLA region,
 189 we imputed HLA alleles at a four digit (two-field) level using HIBAG¹⁹. The only allele that reached
 190 genome-wide significance was HLA-DRB1*04:01 ($OR = 0.80, 95\%CI = 0.75 - 0.86, P = 1.6 \times 10^{-10}$
 191 in EUR), which has a stronger P -value than the lead SNP in the region ($OR : 0.88, 95\%CIs : 0.84 - 0.92, P = 3.3 \times 10^{-9}$
 192 in EUR) and is a better fit to the data ($AIC_{DRB1*04:01} = 30241.34, AIC_{leadSNP} = 30252.93$). Results are shown in supplementary figure 25.

194 Discussion

195 We report 22 replicated genetic associations with life-threatening COVID-19, and 3 additional loci,
 196 discovered in only 7,491 cases. This demonstrates the efficiency of the design of the GenOMICC
 197 study, which is an open-source international research programme²⁰ focusing on critically-ill patients
 198 with infectious disease and other critical illness phenotypes (<https://genomicc.org>). By using whole
 199 genome sequencing we were able to detect multiple distinct signals with high confidence for several
 200 of the associated loci, in some cases implicating different biological mechanisms.

201 Several variants associated with life-threatening disease are linked to interferon signalling. A coding
 202 variant in a ligand, *IFNA10A*, and reduced expression of its receptor *IFNAR2* (Figure 2), were
 203 associated with critical COVID-19. The narrow failure of replication for the *IFNA10* variant

204 (rs28368148, replication $P = 0.00243$, significance threshold $P < 0.002$) may be due to limited power
205 in the replication cohort. The lead variant in *TYK2* in whole genome sequencing is a well-studied
206 protein-coding variant with reduced phosphorylation activity, consistent with that reported recently,⁴
207 but associated with significantly increased *TYK2* expression (Figure 2, Methods). Fine mapping
208 reveals a significant critical illness association with an independent missense variant in *IL10RB*, a
209 receptor for Type III (lambda) interferons (rs28368148,p.Trp164Cys, Table 1). Overall, variants
210 predicted to be associated with reduction in interferon signalling are associated with critical disease.
211 Importantly, systemic administration of interferon in a large clinical trial, albeit late in disease, did
212 not reduce mortality.²¹

213 Phospholipid scramblase 1 (*PLSCR1*; chr3:146517122:G:A) functions as a nuclear signal for the
214 antiviral effect of interferon,²² and has been shown to control replication of other RNA viruses
215 including vesicular stomatitis virus, encephalomyocarditis virus and Influenza A virus.^{23;22} The risk
216 allele at the lead variant (chr3:146517122:G:A, rs343320) encodes a substitution, H262Y, which
217 is predicted to disrupt the non-canonical nuclear localisation signal²⁴ by eliminating a hydrogen
218 bond with importin (Figure 3). Deletion of this nuclear localisation signal has been shown to
219 prevent neutrophil maturation.²⁵ Although *PLSCR1* is strongly up-regulated when membrane lipid
220 asymmetry is lost (see below), it may not act directly on this process.²⁶

221 We report significant associations in several genes implicated in B-cell lymphopoiesis and differentia-
222 tion of myeloid cells. *BCL11A* is essential in B- and T-lymphopoiesis²⁷ and promotes plasmacytoid
223 dendritic cell differentiation.²⁸ *TAC4*, reported previously,⁴ encodes a regulator of B-cell lymphopoe-
224 sis²⁹ and antibody production,³⁰ and promotes survival of dendritic cells.³¹ Finally, although
225 the strongest fine mapping signal at 5q31.1 (chr5:131995059:C:T, rs56162149) is in an intron of
226 *ACSL6* (locus, p), the credible set includes a missense variant in *CSF2* of uncertain significance
227 (chr5:132075767:T:C). *CSF2* encodes granulocyte-macrophage colony stimulating factor, a key
228 differentiation factor in the mononuclear phagocyte system which is strongly up-regulated in critical
229 COVID-19,³² and is already under investigation as a target for therapy.³³

230 Several new genetic associations implicate genes known to be involved in lung disease. The second
231 variant in the credible set at 13q14 (chr13:112882313:A:G, rs1278769, in *ATP11A*), has been reported
232 as a lead variant for idiopathic pulmonary fibrosis.³⁴ *ATP11A* encodes a flippase which maintains
233 the asymmetric distribution of phospholipids in cell membranes;³⁵ disruption of this asymmetry
234 is a phagocytic signal on apoptotic cells, and is required for platelet activation.^{36;37} TWAS
235 and colocalisation demonstrate that genetic variants predicted to decrease expression of *ATP11A* in lung
236 are associated with critical illness. A combination of fine mapping, colocalisation with eQTL signals
237 (GTEx and eQTLgen) and TWAS results provide evidence in support of *MUC1* as the mediator of
238 the association with rs41264915 (Table 1). This may indicate an important role for mucins in the
239 development of critical illness in COVID-19. The direction of effect (Figure 2) suggests that agents
240 that reduce *MUC1* expression, and by extension its abundance, may be a therapeutic option. Finally,
241 the association on 11p13 (rs61882275) includes GTEx eQTL for the lung fibroblast transcription
242 factor *ELF5* in lung tissue, and the gene encoding the antioxidant enzyme catalase (*CAT*) in whole
243 blood with evidence of colocalisation in both signals (supplementary material: TWAS.xlsx).¹⁸ The
244 protective allele at this locus is weakly associated with reduced lung function in a previous GWAS.³⁸

245 *FUT2* encodes alpha-(1,2)fucosyltransferase, which controls the secretion of ABO blood type glycans
246 into body fluids and expression on epithelial surfaces. An association with critical COVID-19 was
247 reported previously in a candidate gene association study by Mankelov et al.³⁹ The credible set for the




Figure 3: (a) Predicted structural consequences of lead variant at *PLSCR1*. Left panel shows the crystal structure of *PLSCR1* nuclear localization signal (orange, Gly257–Ile266, numbering correspond to UniProt entry O15162) in complex with Importin α (blue), Protein Data Bank (PDB) ID 1Y2A. Side chains of *PLSCR1* are shown as connected spheres with carbon atoms coloured in orange, nitrogens in blue and oxygens in red. Hydrogen atoms were not determined at this resolution (2.20 Å) and are not shown. Right panel: a closeup view showing side chains of *PLSCR1* Ser260, His262 and Importin Glu107 as sticks. Distance (in Å) between selected atoms (*PLSCR1* His262 $N\epsilon_2$ and Importin Glu107 carboxyl O) is indicated. A hydrogen bond between *PLSCR1* His262 and Importin Glu107 is indicated with a dashed line. The risk variant is predicted to eliminate this bond, disrupting nuclear import, an essential step for effect on antiviral signalling²² and neutrophil maturation.²⁵ (b) Regional detail showing fine-mapping to separate two adjacent independent signals. Top two panels: variants in linkage disequilibrium with the lead variants shown. The loci that are included in two independent credible sets are displayed with black outline circles. Bottom panel: locations of protein-coding genes, coloured by TWAS P -value.

248 *FUT2* locus includes rs492602 (chr19:48703160:A:G) which is linked to a stop codon gain mutation
249 (chr19:48703417:G:A), leading to the well-described non-secretor phenotype in homozygotes.^{40;41}
250 We show that the stop-gain, non-secretor allele is protective against life-threatening COVID-19.
251 The protective variant in our study has been previously reported to protect against other viruses
252 (rotavirus,⁴² mumps and common colds⁴³), to enhance antibody responses to polyomavirus BK⁴⁴
253 and to increase susceptibility to infection with some encapsulated bacteria.⁴⁵

254 Limitations

255 In contrast to microarray genotyping, whole genome sequencing is rapidly evolving and a relatively
256 new technology for genome-wide association studies, with relatively few sources of population
257 controls. We used selected controls from the 100,000 genomes project, sequenced on a different
258 platform (illumina HiSeqX) from the cases (illumina NovaSeq6000)(Supplementary Table 1). To
259 minimise the risk of false positive associations arising due to sequencing or genotyping errors, we
260 required all significant associations to be supported by local variants in linkage disequilibrium,
261 which may be excessively stringent (see Methods). Although this approach may remove some true
262 associations, our priority is to maximise confidence in the reported signals. Of 25 variants meeting
263 this requirement, 22 are replicated in an independent study, and the remaining 3 may well be true
264 associations that have failed due to a lack of coverage or power in the replication dataset.

265 The design of our study incorporates genetic signals for every stage in the disease progression
266 into a single phenotype. This includes exposure, viral replication, inflammatory lung injury and
267 hypoxaemic respiratory failure. Although we can have considerable confidence that the replicated
268 associations with critical COVID-19 we report are robust, we cannot determine at which stage in
269 the disease process, or in which tissue, the relevant biological mechanisms are active, which can have
270 therapeutic implications.

271 Conclusions

272 The genetic associations here implicate new biological mechanisms underlying the development of
273 life-threatening COVID-19, several of which may be amenable to therapeutic targeting. In the
274 context of the ongoing global pandemic, translation to clinical practice is an urgent priority. As
275 with our previous work, large-scale randomised trials are essential before translating our findings
276 into clinical practice.

277 Acknowledgements

278 We thank the patients and their loved ones who volunteered to contribute to this study at one of the
279 most difficult times in their lives, and the research staff in every intensive care unit who recruited
280 patients at personal risk during the most extreme conditions we have ever witnessed in UK hospitals.

281 GenOMICC was funded by the Department of Health and Social Care (DHSC), LifeArc, the Medical
282 Research Council, UKRI, Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care
283 Society, a Wellcome-Beit Prize award to J. K. Baillie (Wellcome Trust 103258/Z/13/A) and a BBSRC
284 Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172, BBS/E/D/10002070
285 and BBS/E/D/30002275). Whole-genome sequencing was performed by Illumina at the NHS
286 Genomic Sequencing Centre in partnership and was overseen by Genomics England. We would
287 like to thank all at Genomics England who have contributed to the supporting the processing of
288 the sequencing and clinical data. We thank DHSC, the Medical Research Council, UKRI, LifeArc,
289 Genomics England Ltd and Illumina Inc for funding sequencing. Genomics England and the 100,000
290 Genomes Project was funded by the National Institute for Health Research, the Wellcome Trust,
291 the Medical Research Council, Cancer Research UK, the Department of Health and Social Care
292 and NHS England. We are grateful for the support from Professor Dame Sue Hill and the team
293 in NHS England and the 13 Genomic Medicine Centres that successfully delivered the 100,000
294 Genomes Project which provide the control sequences for this study. We thank the participants of
295 the 100,000 Genomes Project who made this study possible and the Genomics England Participant
296 Panel for their strategic advice, involvement and engagement. We acknowledge NHS Digital, Public
297 Health England and the Intensive Care National Audit and Research Centre who provided life course
298 longitudinal clinical data on the participants. This work forms part of the portfolio of research of
299 the NIHR Biomedical Research Centre at Barts. Mark Caulfield is an NIHR Senior Investigator.
300 This study owes a great deal to the National Institute of Healthcare Research Clinical Research
301 Network (NIHR CRN) and the Chief Scientist Office (Scotland), who facilitate recruitment into
302 research studies in NHS hospitals, and to the global ISARIC and InFACT consortia.

303 The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR,
304 MRC, Wellcome Trust or PHE.

305 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office
306 of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and
307 NINDS. The data used for the analyses described in this manuscript were obtained from the GTEx
308 Portal on August 22nd, 2021 (GTEx Analysis Release V8 (dbGaP Accession phs000424.v8.p2)).

309 Data availability

310 Summary statistics will be shared openly with international collaborators to accelerate discovery.
311 Data can be obtained from genomicc.org/data

312 Individual-level data will be available in the UK Outbreak Analysis Platform at the University of
313 Edinburgh and through the Genomics England research environment.

314 **Contributions**

315 AK, EP-C, KR, AS, CAO, SW, TM, KSE, BW, DR, LK, MZ, NP, ADB, JY, YW, SC, LMo, AL and
316 JKB contributed to data analysis. AK, EP-C, KR, AS, CAO, SW, CDR, JM, AR, SC, LMo and AL
317 contributed to bioinformatics. AK, EP-C, KR, CDR, JM, DM, AN, MGS, SC, LMo, MJC and JKB
318 contributed to writing and reviewing the manuscript. EP-C, KR, KM, SK, AF, LM, KRo, CPP,
319 VV, JFW, SC, AL, MJC and JKB contributed to design. SW, FG, WO, PG and SD contributed
320 to project management. FG, WO, KM, SK, PG, SD, DM, AN, MGS, SS, JK, TAF, MS-H, CS,
321 PE, AF, LM, KRo, CPP, RHS, SC and AL contributed to oversight. FG, WO, FM-C and JKB
322 contributed to ethics and governance. KM, ASi, AF and LM contributed to sample handling and
323 sequencing. and ASi contributed to data collection. and TZ contributed to sample handling. TZ
324 and GE contributed to sequencing. and LT contributed to recruitment of controls. GC, PA and
325 KRo contributed to clinical data management. KRo, CPP, SC and JKB contributed to conception.
326 KRo, CPP, VV and JFW contributed to reviewing the manuscript. MJC and JKB contributed to
327 scientific leadership.

328 **Conflict of interest**

329 All authors declare that they have no conflicts of interest relating to this work.

330 Genomics England Ltd is a wholly owned Department of Health and Social Care company created in
331 2013 to work with the NHS to introduce advanced genomic technologies and analytics into healthcare.
332 All Genomics England affiliated authors are, or were, salaried by Genomics England during this
333 programme.

334 **Materials and Methods**

335 **Ethics**

336 GenOMICC was both approved by the following research ethics committees: Scotland "A" Research
337 Ethics Committee, 15/SS/0110; Coventry and Warwickshire Research Ethics Committee (England,
338 Wales and Northern Ireland), 19/WM/0247). Current and previous versions of the study protocol
339 are available at genomicc.org/protocol. All participants gave informed consent.

340 **Recruitment of cases**

341 Patients recruited to the GenOMICC study (genomicc.org) had confirmed COVID-19 according to
342 local clinical testing and were deemed, in the view of the treating clinician, to require continuous
343 cardiorespiratory monitoring. In UK practice this kind of monitoring is undertaken in high-
344 dependency or intensive care units. This study was approved by research ethics committees in the
345 recruiting countries (Scotland 15/SS/0110, England, Wales and Northern Ireland: 19/WM/0247).
346 Current and previous versions of the study protocol are available at genomicc.org/protocol. All
347 participants gave informed consent.

348 **Recruitment of controls**

349 **Mild/asymptomatic controls**

350 Participants were recruited to the mild COVID-19 cohort on the basis of having experienced mild
351 (non-hospitalised) or asymptomatic COVID-19. Participants volunteered to take part in the study
352 via a microsite and were required to self-report the details of a positive COVID-19 test. Volunteers
353 were prioritised for genome sequencing based on demographic matching with the critical COVID-19
354 cohort considering self-reported ancestry, sex, age and location within the UK. We refer to this
355 cohort as the covid-mild cohort.

356 **100,000 Genomes project controls**

357 Participants were enrolled in the 100,000 Genomes Project from families with a broad range of
358 rare diseases, cancers and infection by 13 regional NHS Genomic Medicine Centres across England
359 and in Northern Ireland, Scotland and Wales. For this analysis, participants for whom a positive
360 SARS-CoV-2 test had been recorded as of March, 2021 were not included due to uncertainty in the
361 severity of COVID-19 symptoms. Only participants for whom genome sequencing was performed
362 from blood derived DNA were included and participants with haematological malignancies were
363 excluded to avoid potential tumour contamination.

364 **DNA extraction**

365 For critical COVID-19 cases and mild cohort controls, DNA was extracted from whole blood using
366 Nucleon Kit (Cytiva) with the BACC3 protocol. DNA samples were re-suspended in 1 ml TE buffer
367 pH 7.5 (10mM Tris-Cl pH 7.5, 1mM EDTA pH 8.0). The yield of the DNA was measured using
368 Qubit and normalised to 50ng/ μ l before WGS or genotyping.

369 **WGS sequencing**

370 For all three cohorts, DNA was extracted from whole-blood using standard protocols. Sequencing
371 libraries were generating using the Illumina TruSeq DNA PCR-Free High Throughput Sample
372 Preparation kit and sequenced with 150bp paired-end reads in a single lane of an Illumina HiSeq
373 X instrument (for 100,000 Genomes Project samples) or NovaSeq instrument (for the COVID-19
374 critical and mild cohorts).

375 **Sequencing data QC**

376 All genome sequencing data were required to meet minimum quality metrics and quality control
377 measures were applied for all genomes as part of the bioinformatics pipeline. The minimum data
378 requirements for all genomes were $> 85 \times 10^{-9}$ bases with $Q \geq 30$ and $\geq 95\%$ of the autosomal
379 genome covered at $\geq 15x$ calculated from reads with mapping quality > 10 after removing duplicate
380 reads and overlapping bases, after adaptor and quality trimming. Assessment of germline cross-
381 sample contamination was performed using VerifyBamID and samples with $> 3\%$ contamination
382 were excluded. Sex checks were performed to confirm that the sex reported for a participant was
383 concordant with the sex inferred from the genomic data.

384 **WGS Alignment and variant calling**

385 **COVID-19 cohorts**

386 For the critical and mild COVID-19 cohorts, sequencing data alignment and variant calling was
387 performed with Genomics England pipeline 2.0 which uses the DRAGEN software (v3.2.22). Align-
388 ment was performed to genome reference GRCh38 including decoy contigs and alternate haplotypes
389 (ALT contigs), with ALT-aware mapping and variant calling to improve specificity.

390 **100,000 Genome Project cohort (100K-genomes)**

391 All genomes from the 100,000 Genomes Project cohort were analysed with the Illumina North Star
392 Version 4 Whole Genome Sequencing Workflow (NSV4, version 2.6.53.23); which is comprised of
393 the iSAAC Aligner (version 03.16.02.19) and Starling Small Variant Caller (version 2.4.7). Samples
394 were aligned to the Homo Sapiens NCBI GRCh38 assembly with decoys.

395 A subset of the genomes from the Cancer program of the 100,000 Genomes Project were reprocessed
396 (alignment and variants calling) using the same pipeline used for the COVID-19 cohorts (DRAGEN
397 v3.2.22) for equity of alignment and variant calling.

398 **Aggregation**

399 Aggregation was conducted separately for the samples analysed with Genomics England pipeline 2.0
400 (severe-cohort, mild-cohort, cancer-realigned-100K), and those analysed with the Illumina North
401 Star Version 4 pipeline (100K-Genomes).

402 For the first three, the WGS data were aggregated from single sample gVCF files to multi-sample
403 VCF files using GVCFFGenotyper (GG) v3.8.1, which accepts gVCF files generated via the DRAGEN
404 pipeline as input. GG outputs multi-allelic variants (several ALT variants per position on the same
405 row), and for downstream analyses the output was decomposed to bi-allelic variants per row using
406 software vt v0.57721. We refer to the aggregate as aggCOVID_vX, where X is the specific freeze.
407 The analysis in this manuscript uses data from freeze v4.2 and the respective aggregate is referred
408 to as aggCOVID_v4.2.

409 Aggregation for the 100K-Genomes cohort was performed using Illumina's gvcfgenotyper v2019.02.26,
410 merged with bcftools v1.10.2 and normalised with vt v0.57721.

411 **Sample Quality Control (QC)**

412 Samples that failed any of the following four BAM-level QC filters: freemix contamination (>3%),
413 mean autosomal coverage (<25X), percent mapped reads (<90%), and percent chimeric reads (>5%)
414 were excluded from the analysis.

415 Additionally, a set of VCF-level QC filters were applied post-aggregation on all autosomal bi-allelic
416 SNVs (akin to gnomAD v3.1¹⁷). Samples were filtered out based on the residuals of eleven QC metrics
417 (calculated using bcftools) after regressing out the effects of sequencing platform and the first three
418 ancestry assignment principal components (including all linear, quadratic, and interaction terms)
419 taken from the sample projections onto the SNP loadings from the individuals of 1000 Genomes
420 Project phase 3 (1KGP3). Samples were removed that were four median absolute deviations (MADs)

421 above or below the median for the following metrics: ratio heterozygous-homozygous, ratio insertions-
422 deletions, ratio transitions-transversions, total deletions, total insertions, total heterozygous snps,
423 total homozygous snps, total transitions, total transversions. For the number of total singletons
424 (snps), samples were removed that were more than 8 MADs above the median. For the ratio of
425 heterozygous to homozygous alternate snps, samples were removed that were more than 4 MADs
426 above the median.

427 After quality control, 79,803 individuals were included in the analysis with the breakdown according
428 to cohort shown in Supplementary Table 2.

429 Selection of high-quality (HQ) independent SNPs

430 We selected high-quality independent variants for inferring kinship coefficients, performing PCA,
431 assigning ancestry and for the conditioning on the Genetic Relatedness matrix by the logistic mixed
432 model of SAIGE and SAIGE-GENE. To avoid capturing platform and/or analysis pipeline effects
433 for these analyses, we performed very stringent variant QC as described below.

434 HQ common SNPs

435 We started with autosomal, bi-allelic SNPs which had frequency $> 5\%$ in aggV2 (100K participant
436 aggregate) and in the 1KGP3. We then restricted to variants that had missingness $< 1\%$, median
437 genotype quality $QC > 30$, median depth (DP) ≥ 30 and $\geq 90\%$ of heterozygote genotypes passing
438 an ABratio binomial test with P -value $> 10^{-2}$ for aggV2 participants. We also excluded variants in
439 complex regions from the list available in , and variants where the ref/alt combination was CG or AT
440 (C/G, G/C, A/T, T/A). We also removed all SNPs which were out of Hardy Weinberg Equilibrium
441 (HWE) in any of the AFR, EAS, EUR or SAS super-populations of aggV2, with a P -value cutoff of
442 $pHWE < 10^{-5}$. We then LD-pruned using plink v1.9 with an $r^2 = 0.1$ and in 500kb windows. This
443 resulted in a total of 63,523 high-quality sites from aggV2.

444 We then extracted these high-quality sites from the aggCOVID_v4.2 aggregate and further applied
445 variant quality filters (missingness $< 1\%$, median $QC > 30$, median depth ≥ 30 and $\geq 90\%$ of
446 heterozygote genotypes passing an ABratio binomial test with P -value $> 10^{-2}$), per batch of
447 sequencing platform (i.e, HiseqX, NovaSeq6000).

448 After applying variant filters in aggV2 and aggCOVID_v4.2, we merged the genomic data from the
449 two aggregates for the intersection of the variants which resulted in a final total of 58,925 sites.

450 HQ rare SNPs

451 We selected high-quality rare ($MAF < 0.005$) bi-allelic SNPs to be used with SAIGE for aggregate
452 variant testing analysis. To create this set, we applied the same variant QC procedure as with
453 the common variants: We selected variants that had missingness $< 1\%$, median $QC > 30$, median
454 depth ≥ 30 and $\geq 90\%$ of heterozygote genotypes passing an ABratio binomial test with P -value
455 $> 10^{-2}$ per batch of sequencing and genotyping platform (i.e, HiSeq+NSV4, HiSeq+Pipeline 2.0,
456 NovaSeq+Pipeline 2.0). We then subsetted those to the following groups of MAC/MAF categories:
457 MAC 1, 2, 3, 4, 5, 6-10, 11-20, MAC 20 - MAF 0.001, MAF 0.001 - 0.005.

458 **Relatedness, ancestry and principal components**

459 **Kinship**

460 We calculated kinship coefficients among all pairs of samples using software plink2 and its imple-
461 mentation of the KING robust algorithm. We used a kinship cutoff < 0.0442 to select unrelated
462 individuals with argument “-king-cutoff”.

463 **Genetic Ancestry Prediction**

464 To infer the ancestry of each individual we performed principal components analysis (PCA) on
465 unrelated 1KGP3 individuals with GCTA v1.93.1_beta software using HQ common SNPs and
466 inferred the first 20 PCs. We calculated loadings for each SNP which we used to project aggV2 and
467 aggCOVID_v4.2 individuals onto the 1KGP3 PCs. We then trained a random forest algorithm
468 from R-package randomForest with the first 10 1KGP3 PCs as features and the super-population
469 ancestry of each individual as labels. These were ‘AFR’ for individuals of African ancestry, ‘AMR’
470 for individuals of American ancestry, ‘EAS’ for individuals of East Asian ancestry, ‘EUR’ for
471 individuals of European ancestry, and ‘SAS’ for individuals of South Asian ancestry. We used
472 500 trees for the training. We then used the trained model to assign probability of belonging to
473 a certain super-population class for each individual in our cohorts. We assigned individuals to a
474 super-population when class probability ≥ 0.8 . Individuals for which no class had probability
475 ≥ 0.8 were labelled as “unassigned” and were not included in the analyses.

476 **Principal component analysis**

477 After labelling each individual with predicted genetic ancestry, we calculated ancestry-specific PCs
478 using GCTA v1.93.1_beta, *i.e.*. We computed 20 PCs for each of the ancestries that were used in
479 the association analyses (AFR, EAS, EUR, and SAS).

480 **Variant Quality Control**

481 Variant QC was performed to ensure high quality of variants and to minimise batch effects due to
482 using samples from different sequencing platforms (NovaSeq6000 and HiseqX) and different variant
483 callers (Strelka2 and DRAGEN). We first masked low-quality genotypes setting them to missing,
484 merged aggregate files and then performed additional variant quality control separately for the two
485 major types of association analyses, GWAS and AVT, which concerned common and rare variants,
486 respectively.

487 **Masking**

488 Prior to any analysis we masked low quality genotypes using bcftools setGT module. Genotypes
489 with $DP < 10$, $GQ < 20$, and heterozygote genotypes failing an AB-ratio binomial test with P -value $<$
490 10^{-3} were set to missing.

491 We then converted the masked VCF files to plink and bgen format using plink v.2.0.

492 **Merging of aggregate samples**

493 Merging of aggV2 and aggCOVID_v4.2 samples was done using plink files with masked genotypes
494 and the merge function of plink v.1.9.⁴⁶ for variants that were found in both aggregates.

495 **GWAS analyses**

496 **Variant QC**

497 We restricted all GWAS analyses to common variants applying the following filters using plink v1.9:
498 $MAF > 0$ in both cases and controls, $MAF > 0.5\%$ and $MAC > 20$, missingness $< 2\%$, Differential
499 missingness between cases and controls, mid- P -value $< 10^{-5}$, HWE deviations on unrelated controls,
500 mid- P -value $< 10^{-6}$, Multi-allelic variants were additionally required to have $MAF > 0.1\%$ in both
501 aggV2 and aggCOVID_v4.2.

502 **Control-control QC filter**

503 100K aggV2 samples that were aligned and genotype called with the Illumina North Star Version 4
504 pipeline represented the majority of control samples in our GWAS analyses, whereas all of the cases
505 were aligned and called with Genomics England pipeline 2.0 (Supplementary Table 1). Therefore,
506 the alignment and genotyping pipelines partially match the case/control status which necessitates
507 additional filtering for adjusting for between-pipeline differences in alignment and variant calling. To
508 control for potential batch effects, we used the overlap of 3,954 samples from the Genomics England
509 100K participants that were aligned and called with both pipelines. For each variant, we computed
510 and compared between platforms the inferred allele frequency for the population samples. We then
511 filtered out all variants that had $> 1\%$ relative difference in allele frequency between platforms. The
512 relative difference was computed on a per-population basis for EUR ($n=3,157$), SAS ($n=373$), AFR
513 ($n=354$) and EAS ($n=81$).

514 **Model**

515 We used a 2-step logistic mixed model regression approach as implemented in SAIGE v0.44.5 for
516 single variant association analyses. In step 1, SAIGE fits the null mixed model and covariates. In
517 step 2, single variant association tests are performed with the saddlepoint approximation (SPA)
518 correction to calibrate unbalanced case-control ratios. We used the HQ common variant sites for
519 fitting the null model and *sex*, *age*, *age*², *age* * *sex* and 20 principal components as covariates in
520 step 1. The principal components were computed separately by predicted genetic ancestry (i.e.,
521 EUR-specific, AFR-specific, etc.), to capture subtle structure effects.

522 **Analyses**

523 All analyses were done on unrelated individuals with pairwise kinship coefficient < 0.0442 . We
524 conducted GWAS analyses per genetic ancestry, for all populations for which we had >100 cases
525 and >100 controls (AFR, EAS, EUR, and SAS).

526 **Multiple testing correction**

527 As our study is testing variants that were directly sequenced by WGS and not imputed, we calculated
528 the P -value significance threshold by estimating the effective number of tests. After selecting the

529 final filtered set of tested variants for each population, we LD-pruned in a window of 250Kb and
530 $r^2 = 0.8$ with plink 1.9. We then computed the Bonferroni-corrected P -value threshold as 0.05
531 divided by the number of LD-pruned variants. The P -value thresholds that were used for declaring
532 statistical significance are given in Supplementary Table 3.

533 **LD-clumping**

534 We used plink1.9 to do clumping of variants that were genome-wide significant for each analysis with
535 $P1$ set to per-population P -value from table X, $P2 = 0.01$, clump distance 1500Mb and $r^2 = 0.1$.

536 **Conditional analysis**

537 To find the set of independent variants in the per-population analyses, we performed a step-wise
538 conditional analysis with the GWAS summary statistics for each population using GTCA 1.9.3
539 `-cojo-slc` function. The parameters for the function were $pval = 2.2 \times 10^{-8}$, a distance of 10,000 kb
540 and a colinear threshold of 0.9⁴⁷.

541 **Fine-mapping**

542 We performed fine-mapping for genome-wide significant signals using Rpackage SusieR v0.11.42⁴⁸.
543 For each genome-wide significant variant locus, we selected the variants 1.5 Mbp on each side and
544 computed the correlation matrix among them with plink v1.9. We then run the susieR summary-
545 statistics based function `susie_rss` and provided the summary z-scores from SAIGE (i.e, effect size
546 divided by its standard error) and the correlation matrix computed with the same samples that
547 were used for the corresponding GWAS. We required coverage >0.95 for each identified credible set
548 and minimum and median correlation coefficients (purity) of $r=0.1$ and 0.5, respectively.

549 **Functional annotation of credible sets**

550 We annotated all variants included in each credible set identified by SusieR using VEP v99. We also
551 selected the worst consequence across transcripts using `bcftools +split-vep -s worst`. We also ranked
552 each variant within each credible set according to the predicted consequence and the ranking was
553 based on the table provided by Ensembl: https://www.ensembl.org/info/genome/variation/prediction/predicted_data.html.
554

555 **Trans-ancestry meta-analysis**

556 We performed a meta-analysis across all ancestries using an inverse-variance weighted method and
557 control for population stratification for each separate analysis in the METAL software¹³. The
558 meta-analysed variants were filtered for variants with heterogeneity P -value $p < 2.22 \times 10^{-8}$ and
559 variants that are not present in at least half of the individuals. We used the meta R package to plot
560 forest plots of the clumped trans-ancestry meta-analysis variants⁴⁹.

561 **LD-based validation of lead GWAS signals**

In order to quantify the support for genome-wide significant signals from nearby variants in LD, we assessed the internal consistency of GWAS results of the lead variants and their surroundings. To this end, we compared observed z-scores at lead variants with the expected z-scores based on those

observed at neighbouring variants. Specifically, we computed the observed z-score for a variant i as $s_i = \hat{\beta}/\hat{\sigma}_{\beta}$ and, following the approach of⁵⁰, the imputed z-score at a target variant t as

$$\hat{s}_t = \mathbf{\Sigma}_{t,P}(\mathbf{\Sigma}_{P,P} + \lambda\mathbf{I})^{-1}\mathbf{s}_P$$

562 where \mathbf{s}_P are the observed z-scores at a set P of predictor variants, $\mathbf{\Sigma}_{x,y}$ is the empirical correlation
563 matrix of dosage coded genotypes computed on the GWAS sample between the variants in x and y ,
564 and λ is a regularization parameter set to 10^{-5} . The set P of predictor variants consisted of all
565 variants within 100 kb of the target variant with a genotype correlation with the target variant
566 greater than 0.25.

567 Replication

568 We used the Host Genetic Initiative (HGI) GWAS meta-analysis round 6 hospitalised COVID vs
569 population (B2 analysis), including all genetic ancestries. In order to remove overlapping signals
570 we performed a mathematical subtraction of the GenOMICC GWAS of European genetic ancestry.
571 The HGI data was downloaded from <https://www.covid19hg.org/results/r6/>. The subtraction was
572 performed using MetaSubtract package (version 1.60) for R (version 4.0.2) after removing variants
573 with the same genomic position and using the lambda.cohortswith genomic inflation calculated on
574 the GenOMICC summary statistics. Then, we calculated a trans-ancestry meta-analysis for the three
575 ancestries with summary statistics in 23andMe: African, Latino and European using variants that
576 passed the 23andMe ancestry QC, with imputation score > 0.6 and with $\text{maf} > 0.005$. And finally
577 we performed a final meta-analysis of 23andMe and HGI B2 without GenOMICC to create the final
578 replication set. Meta-analysis were performed using METAL¹³, with the inverse-variance weighting
579 method (STDERR mode) and genomic control ON. We considered that a hit was replicating if the
580 direction of effect in the GenOMICC-subtracted HGI summary statistics was the same as in our
581 GWAS, and the P -value was significant after Bonferroni correction for the number of attempted
582 replications ($pval < 0.05/25$). If the main hit was not present in the HGI-23andMe meta-analysis or
583 if the hit was not replicating we looked for replication in variants in high LD with the top variant
584 ($r^2 > 0.9$), which helped replicate two regions.

585 Stratified analysis

586 We also performed sex-specific analysis (male and females separately) as well as analysis stratified
587 by age (*i.e.*, participants < 60 and ≥ 60 years old) for each super-population set. To compare effect
588 of variants within groups for the age and sex stratified analysis we first adjusted the effect and error
589 of each variant for the standard deviation of the trait in each stratified group and then used the
590 following t-statistic, as in previous studies^{51;52}

$$591 \quad t = \frac{b_1 - b_2}{\sqrt{se_1^2 + se_2^2 - 2 \cdot r \cdot se_1 \cdot se_2}}$$

592 where b_1 is the adjusted effect for group 1, b_2 is the adjusted effect for group 2, se_1 and se_2 are
593 the adjusted standard errors for group 1 and 2 respectively and r is the Spearman rank correlation
594 between groups across all genetic variants.

595 HLA Imputation and Association Analysis

596 HLA types were imputed at two field (4-digit) resolution for all samples within aggV2 and ag-
597 gCOVID_v4.2 for the following seven loci: HLA-A, HLA-C, HLA-B, HLA-DRB1, HLA-DQA1,

598 HLA-DQB1, and HLA-DPB1 using the HIBAG package in R¹⁹. At time of writing, HLA types
599 were also imputed for 82% of samples using HLA*LA⁵³. Inferred HLA alleles between HIBAG and
600 HLA*LA were >96% identical at 4-digit resolution. HLA association analysis was run under an
601 additive model using SAIGE; in an identical fashion to the SNV GWAS. The multi-sample VCF
602 of aggregated HLA type calls from HIBAG were used as input where any allele call with posterior
603 probability (T) < 0.5 were set to missing.

604 **Aggregate variant testing (AVT)**

605 Aggregate variant testing on aggCOVID_v4.2 was performed using SKAT-O as implemented in
606 SAIGE-GENE v0.44.5¹⁶ on all protein-coding genes. Variant and sample QC for the preparation
607 and masking of the aggregate files has been described elsewhere. We further excluded SNPs with
608 differential missingness between cases and controls (mid-P value < 10^{-5}) or a site-wide missingness
609 above 5%. Only bi-allelic SNPs with a MAF < 0.5% were included.

610 We filtered the variants to include in the aggregate variant testing by applying two functional
611 annotation filters: A putative loss of function (*pLoF*) filter, where only variants that are annotated
612 by LOFTEE¹⁷ as high confidence loss of function were included, and a more lenient (*missense*)
613 filter where variants that have a consequence of missense or worse as annotated by VEP, with a
614 CADD_PHRED score of ≥ 10 , were also included. All variants were annotated using VEP v99.
615 SAIGE-GENE was run with the same covariates used in the single variant analysis: *sex*, *age*, *age*²,
616 *age * sex* and 20 (population-specific) principal components generated from common variants (MAF
617 $\geq 5\%$).

618 We ran the tests separately by genetically predicted ancestry, as well as across all four ancestries as
619 a mega-analysis. We considered a gene-wide significant threshold on the basis of the genes tested
620 per ancestry, correcting for the two masks (*pLoF* and *missense*, Supplementary Table 4).

621 **Post-GWAS analysis**

622 **Transcriptome-wide Association Studies (TWAS)**

623 We performed TWAS in the MetaXcan framework and the GTEExv8 eQTL and sQTL MASHR-M
624 models available for download in (<http://predictdb.org/>). We first calculated, using the European
625 summary statistics, individual TWAS for whole blood and lung with the S-PrediXcan function^{54;55}.
626 Then we performed a metaTWAS including data from all tissues to increase statistical power using
627 s-MultiXcan⁵⁶. We applied Bonferroni correction to the results in order to choose significant genes
628 and introns for each analysis.

629 **Colocalisation analysis**

630 Significant genes from TWAS, splicing TWAS, metaTWAS and splicing metaTWAS, as well as genes
631 where one of the top variants was a significant eQTL or sQTL were selected for a colocalisation
632 analysis using the coloc R package⁵⁷. We chose the lead SNPs from the European ancestry GWAS
633 summary statistics and a region of ± 200 kb around each SNP to do the colocalisation with the
634 identified genes in the region. GTEExv8 whole blood and lung tissue summary statistics and eqtlGen
635 (which has blood eQTL summary statistics for > 30,000 individuals) were used for the analysis^{18;58}.
636 We first performed a sensitivity analysis of the posterior probability of colocalisation (PPH4) on the

637 prior probability of colocalisation (p_{12}), going from $p_{12} = 10^{-8}$ to $p_{12} = 10^{-4}$ with the default
638 threshold being $p_{12} = 10^{-5}$. eQTL signal and GWAS signals were deemed to colocalise if these
639 two criteria were met: (1) At $P_{12} = 5 \times 10^{-5}$ the probability of colocalisation $PPH4 > 0.5$ and
640 (2) At $p_{12} = 10^{-5}$ the probability of independent signal (PPH3) was not the main hypothesis
641 ($PPH3 < 0.5$). These criteria were chosen to allow eQTLs with weaker P -values due to lack of
642 power in GTEXv8, to be colocalised with the signal when the main hypothesis using small priors
643 was that there wasn't any signal in the eQTL data.

644 As the chromosome 3 associated interval is larger than 200 kb, we performed additional colocalisation
645 including a region up to 500 kb, but no further colocalisations were found.

646 References

- 647 [1] Pairo-Castineira, E. *et al.* Genetic mechanisms of critical illness in Covid-19. *Nature* 1–1 (2020).
- 648 [2] Zhang, Q. *et al.* Inborn errors of type I IFN immunity in patients with life-threatening COVID-
649 19. *Science (New York, N.y.)* **370**, eabd4570 (2020). URL [https://www.ncbi.nlm.nih.gov/pmc/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857407/)
650 [articles/PMC7857407/](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857407/).
- 651 [3] Ellinghaus, D. *et al.* Genomewide association study of severe covid-19 with respiratory failure.
652 *The New England journal of medicine* **383**, 1522–1534 (2020).
- 653 [4] COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19.
654 *Nature* (2021). URL <https://doi.org/10.1038/s41586-021-03767-x>.
- 655 [5] Docherty, A. B. *et al.* Features of 20 133 UK patients in hospital with covid-19 using the
656 ISARIC WHO Clinical Characterisation Protocol: Prospective observational cohort study. *BMJ*
657 **369** (2020).
- 658 [6] Dorward, D. A. *et al.* Tissue-Specific Immunopathology in Fatal COVID-19. *American Journal*
659 *of Respiratory and Critical Care Medicine* **203**, 192–201 (2021).
- 660 [7] Millar, J. E. *et al.* Robust, reproducible clinical patterns in hospitalised patients with COVID-19.
661 *medRxiv* 2020.08.14.20168088 (2020).
- 662 [8] Horby, P. *et al.* Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report.
663 *New England Journal of Medicine* (2020).
- 664 [9] Degenhardt, F. *et al.* New susceptibility loci for severe COVID-19 by detailed GWAS analysis
665 in European populations (2021).
- 666 [10] Kosmicki, J. A. *et al.* Pan-ancestry exome-wide association analyses of COVID-19 outcomes
667 in 586,157 individuals. *American Journal of Human Genetics* **108**, 1350–1355 (2021). URL
668 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8173480/>.
- 669 [11] Povysil, G. *et al.* Rare loss-of-function variants in type i ifn immunity genes are not associated
670 with severe covid-19. *The Journal of clinical investigation* **131** (2021).
- 671 [12] Zhou, W. *et al.* Efficiently controlling for case-control imbalance and sample relatedness in
672 large-scale genetic association studies. *Nature Genetics* **50**, 1335–1341 (2018). URL [http:](http://www.nature.com/articles/s41588-018-0184-y)
673 [//www.nature.com/articles/s41588-018-0184-y](http://www.nature.com/articles/s41588-018-0184-y).

- 674 [13] Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide
675 association scans. *Bioinformatics (Oxford, England)* **26**, 2190–2191 (2010).
- 676 [14] Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
677 selection in regression, with application to genetic fine mapping. *Journal of the Royal Statistical*
678 *Society: Series B (Statistical Methodology)* **82**, 1273–1300 (2020). URL [https://rss.onlinelibrar](https://rss.onlinelibrary.wiley.com/doi/full/10.1111/rssb.12388)
679 [y.wiley.com/doi/full/10.1111/rssb.12388](https://rss.onlinelibrary.wiley.com/doi/abs/10.1111/)<https://rss.onlinelibrary.wiley.com/doi/abs/10.1111/>
680 [rssb.12388https://rss.onlinelibrary.wiley.com/doi/10.1111/rssb.12388](https://rss.onlinelibrary.wiley.com/doi/10.1111/rssb.12388).
- 681 [15] Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting
682 the deleteriousness of variants throughout the human genome. *Nucleic Acids Research* **47**,
683 D886–D894 (2018). URL <https://doi.org/10.1093/nar/gky1016>.
- 684 [16] Zhou, W. *et al.* Scalable generalized linear mixed model for region-based association tests in
685 large biobanks and cohorts. *Nature Genetics* **52**, 634–639 (2020). URL [https://www.nature.c](https://www.nature.com/articles/s41588-020-0621-6)
686 [om/articles/s41588-020-0621-6](https://www.nature.com/articles/s41588-020-0621-6).
- 687 [17] Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
688 141,456 humans. *Nature* **581**, 434–443 (2020). URL [https://www.nature.com/articles/s41586-](https://www.nature.com/articles/s41586-020-2308-7)
689 [020-2308-7](https://www.nature.com/articles/s41586-020-2308-7).
- 690 [18] Consortium, T. G. The GTEx Consortium atlas of genetic regulatory effects across human
691 tissues. *Science* **369**, 1318–1330 (2020). URL [https://science.sciencemag.org/content/3](https://science.sciencemag.org/content/369/6509/1318)
692 [69/6509/1318](https://science.sciencemag.org/content/369/6509/1318). Publisher: American Association for the Advancement of Science _eprint:
693 <https://science.sciencemag.org/content/369/6509/1318.full.pdf>.
- 694 [19] Zheng, X. *et al.* HIBAG - HLA genotype imputation with attribute bagging. *Pharmacogenomics*
695 *Journal* **14**, 192–200 (2014).
- 696 [20] Dunning, J. W. *et al.* Open source clinical science for emerging infections. *The Lancet Infectious*
697 *Diseases* **14**, 8–9 (2014).
- 698 [21] Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. *New*
699 *England Journal of Medicine* **0**, null (2020).
- 700 [22] Dong, B. *et al.* Phospholipid scramblase 1 potentiates the antiviral activity of interferon.
701 *Journal of virology* **78**, 8983–93 (2004).
- 702 [23] Luo, W. *et al.* Phospholipid scramblase 1 interacts with influenza a virus np, impairing its
703 nuclear import and thereby suppressing virus replication. *PLoS pathogens* **14**, e1006851 (2018).
- 704 [24] Chen, M.-H. *et al.* Phospholipid Scramblase 1 Contains a Nonclassical Nuclear Localization
705 Signal with Unique Binding Site in Importin A*. *Journal of Biological Chemistry* **280**, 10599–
706 10606 (2005).
- 707 [25] Chen, C.-W., Sowden, M., Zhao, Q., Wiedmer, T. & Sims, P. J. Nuclear phospholipid scramblase
708 1 prolongs the mitotic expansion of granulocyte precursors during G-CSF-induced granulopoiesis.
709 *Journal of Leukocyte Biology* **90**, 221–233 (2011).
- 710 [26] Bevers, E. M. & Williamson, P. L. Phospholipid scramblase: An update. *FEBS Letters* **584**,
711 2724–2730 (2010).

- 712 [27] Yu, Y. *et al.* Bcl11a is essential for lymphoid development and negatively regulates p53. *The*
713 *Journal of experimental medicine* **209**, 2467–83 (2012).
- 714 [28] Reizis, B. Plasmacytoid Dendritic Cells: Development, Regulation, and Function. *Immunity*
715 **50**, 37–50 (2019).
- 716 [29] Zhang, Y., Lu, L., Furlonger, C., Wu, G. E. & Paige, C. J. Hemokinin is a hematopoietic-specific
717 tachykinin that regulates b lymphopoiesis. *Nature immunology* **1**, 392–7 (2000).
- 718 [30] Wang, W. *et al.* Hemokinin-1 activates the mapk pathway and enhances b cell proliferation
719 and antibody production. *Journal of immunology (Baltimore, Md. : 1950)* **184**, 3590–7 (2010).
- 720 [31] Janeloins, B. M. *et al.* Proinflammatory tachykinins that signal through the neurokinin 1
721 receptor promote survival of dendritic cells and potent cellular immunity. *Blood* **113**, 3017–26
722 (2009).
- 723 [32] Thwaites, R. S. *et al.* Inflammatory profiles across the spectrum of disease reveal a distinct role
724 for GM-CSF in severe COVID-19. *Science Immunology* **6** (2021).
- 725 [33] Lang, F. M., Lee, K. M.-C., Teijaro, J. R., Becher, B. & Hamilton, J. A. Gm-csf-based treatments
726 in covid-19: reconciling opposing therapeutic approaches. *Nature reviews. Immunology* **20**,
727 507–514 (2020).
- 728 [34] Moore, C. *et al.* Resequencing Study Confirms That Host Defense and Cell Senescence Gene
729 Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. *American Journal of*
730 *Respiratory and Critical Care Medicine* **200**, 199–208 (2019). URL [https://www.atsjournals.or](https://www.atsjournals.org/doi/10.1164/rccm.201810-1891OC)
731 [g/doi/10.1164/rccm.201810-1891OC](https://www.atsjournals.org/doi/10.1164/rccm.201810-1891OC). Publisher: American Thoracic Society - AJRCCM.
- 732 [35] Takatsu, H. *et al.* Phospholipid flippase activities and substrate specificities of human type iv
733 p-type atpases localized to the plasma membrane. *The Journal of biological chemistry* **289**,
734 33543–56 (2014).
- 735 [36] Bevers, E. M., Comfurius, P. & Zwaal, R. F. Changes in membrane phospholipid distribution
736 during platelet activation. *Biochimica et biophysica acta* **736**, 57–66 (1983).
- 737 [37] Zwaal, R. F., Comfurius, P. & van Deenen, L. L. Membrane asymmetry and blood coagulation.
738 *Nature* **268**, 358–60 (1977).
- 739 [38] Shrine, N. *et al.* New genetic signals for lung function highlight pathways and chronic obstructive
740 pulmonary disease associations across multiple ancestries. *Nature genetics* **51**, 481–493 (2019).
- 741 [39] Mankelov, T. J. *et al.* Blood group type A secretors are associated with a higher risk of
742 COVID-19 cardiovascular disease complications. *eJHaem* **2**, 175–187 (2021).
- 743 [40] Kelly, R. J., Rouquier, S., Giorgi, D., Lennon, G. G. & Lowe, J. B. Sequence and expression
744 of a candidate for the human secretor blood group alpha(1,2)fucosyltransferase gene (fut2).
745 homozygosity for an enzyme-inactivating nonsense mutation commonly correlates with the
746 non-secretor phenotype. *The Journal of biological chemistry* **270**, 4640–9 (1995).
- 747 [41] Ferrer-Admetlla, A. *et al.* A natural history of fut2 polymorphism in humans. *Molecular biology*
748 *and evolution* **26**, 1993–2003 (2009).

- 749 [42] Imbert-Marcille, B.-M. *et al.* A fut2 gene common polymorphism determines resistance to
750 rotavirus a of the p[8] genotype. *The Journal of infectious diseases* **209**, 1227–30 (2014).
- 751 [43] Tian, C. *et al.* Genome-wide association and hla region fine-mapping studies identify suscepti-
752 bility loci for multiple common infections. *Nature communications* **8**, 599 (2017).
- 753 [44] Kachuri, L. *et al.* The landscape of host genetic factors involved in immune response to common
754 viral infections. *medRxiv : the preprint server for health sciences* (2020).
- 755 [45] Blackwell, C. C. *et al.* Non-secretion of abo antigens predisposing to infection by neisseria
756 meningitidis and streptococcus pneumoniae. *Lancet (London, England)* **2**, 284–5 (1986).
- 757 [46] Purcell, S. *et al.* PLINK: A Tool Set for Whole-Genome Association and Population-Based
758 Linkage Analyses. *The American Journal of Human Genetics* **81**, 559–575 (2007). URL
759 <https://www.sciencedirect.com/science/article/pii/S0002929707613524>.
- 760 [47] Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics
761 identifies additional variants influencing complex traits. *Nature Genetics* **44**, 369–375 (2012).
762 URL <https://doi.org/10.1038/ng.2213>.
- 763 [48] Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable
764 selection in regression, with application to genetic fine mapping. *Journal of the Royal Statistical*
765 *Society Series B (Statistical Methodology)* **82**, 1273–1300 (2020). URL [https://rss.onlinelibrary.](https://rss.onlinelibrary.wiley.com/doi/10.1111/rssb.12388)
766 [wiley.com/doi/10.1111/rssb.12388](https://doi.org/10.1111/rssb.12388).
- 767 [49] Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: a practical
768 tutorial. *Evidence-Based Mental Health* **22**, 153–160 (2019). URL [https://ebmh.bmj.com/con](https://ebmh.bmj.com/content/22/4/153)
769 [tent/22/4/153](https://doi.org/10.1136/ebmh-2019-000153). Publisher: Royal College of Psychiatrists Section: Statistics in practice.
- 770 [50] Pasaniuc, B. *et al.* Fast and accurate imputation of summary statistics enhances evidence
771 of functional enrichment. *Bioinformatics* **30**, 2906–2914 (2014). URL [https://doi.org/](https://doi.org/10.1093/bioinformatics/btu416)
772 [10.1093/bioinformatics/btu416](https://doi.org/10.1093/bioinformatics/btu416). [https://academic.oup.com/bioinformatics/article-](https://academic.oup.com/bioinformatics/article-pdf/30/20/2906/17147061/btu416.pdf)
773 [pdf/30/20/2906/17147061/btu416.pdf](https://doi.org/10.1093/bioinformatics/btu416).
- 774 [51] Winkler, T. W. *et al.* The influence of age and sex on genetic associations with adult body size
775 and shape: A large-scale genome-wide interaction study. *PLOS Genetics* **11**, 1–42 (2015). URL
776 <https://doi.org/10.1371/journal.pgen.1005378>.
- 777 [52] Bernabeu, E. *et al.* Sexual differences in genetic architecture in uk biobank. *bioRxiv* (2020).
778 URL <https://www.biorxiv.org/content/early/2020/07/21/2020.07.20.211813>. [https://](https://www.biorxiv.org/content/early/2020/07/21/2020.07.20.211813.full.pdf)
779 www.biorxiv.org/content/early/2020/07/21/2020.07.20.211813.full.pdf.
- 780 [53] Diltthey, A. T. *et al.* HLA*LA—HLA typing from linearly projected graph alignments. *Bioin-*
781 *formatics* **35**, 4394–4396 (2019). URL <https://doi.org/10.1093/bioinformatics/btz235>.
782 <https://academic.oup.com/bioinformatics/article-pdf/35/21/4394/30330845/btz235.pdf>.
- 783 [54] Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression
784 variation inferred from GWAS summary statistics. *Nature Communications* **9**, 1825 (2018).
785 URL <https://doi.org/10.1038/s41467-018-03621-1>.

- 786 [55] Gamazon, E. R. *et al.* A gene-based association method for mapping traits using reference
787 transcriptome data. *Nature Genetics* **47**, 1091–1098 (2015). URL [https://doi.org/10.1038/ng.3](https://doi.org/10.1038/ng.3367)
788 367.
- 789 [56] Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves
790 association detection. *PLOS Genetics* **15**, 1–20 (2019). URL [https://doi.org/10.1371/journal.](https://doi.org/10.1371/journal.pgen.1007889)
791 pgen.1007889. Publisher: Public Library of Science.
- 792 [57] Giambartolomei, C. *et al.* Bayesian Test for Colocalisation between Pairs of Genetic Association
793 Studies Using Summary Statistics. *PLOS Genetics* **10**, e1004383 (2014). URL [https://journals](https://journals.plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004383)
794 .plos.org/plosgenetics/article?id=10.1371/journal.pgen.1004383. Publisher: Public Library of
795 Science.
- 796 [58] Vösa, U. *et al.* Unraveling the polygenic architecture of complex traits using blood eQTL
797 metaanalysis. *bioRxiv* 447367 (2018). URL [http://biorxiv.org/content/early/2018/10/19/447](http://biorxiv.org/content/early/2018/10/19/447367.abstract)
798 367.abstract.